<p>Immix Biopharma, Inc.（納斯達克股票代碼：IMMX - 獲取免費報告）在六月份成為空頭頭寸顯著增加的目標。截至 6 月 15 日，空頭頭寸總計 473,100 股，比 5 月 31 日的 338,700 股增加了 39.7%。根據平均每日交易量 131,400 股，目前的空頭頭寸比率為 3.6 天。目前，公司股份中有 3.1% 被做空。</p>
<p>獲取 <strong>Immix Biopharma</strong> 警報：</p>
<h2>華爾街分析師觀點</h2>
<p>另外，HC Wainwright 在週一的一份報告中開始對 Immix Biopharma 進行覆蓋。他們對該股發出了 “買入” 評級，並設定了 7.00 美元的股價目標。</p>
<p><strong>查看我們對 Immix Biopharma 的最新分析</strong></p>
<h2>Immix Biopharma 交易上漲 7.1%</h2>
<p>IMMX 週一在交易時間內上漲了 0.14 美元，達到 2.12 美元。公司股票交易量為 109,687 股，相比其平均交易量 209,798 股有所下降。Immix Biopharma 的 12 個月最低價為 1.55 美元，最高價為 7.75 美元。該公司的市值為 5599 萬美元，市盈率為-2.28，貝塔係數為 0.17。公司的 50 天移動平均價為 2.16 美元，200 天移動平均價為 3.42 美元。</p>
<p>Immix Biopharma（納斯達克股票代碼：IMMX - 獲取免費報告）上次公佈季度財報是在 5 月 9 日星期四。公司報告該季度每股收益為（0.22）美元，超過了（0.23）美元的共識預期。研究分析師羣體預計，Immix Biopharma 今年財政年度的每股收益將為-0.93 美元。</p>
<h2>機構投資者對 Immix Biopharma 的看法</h2>
<p>一些對沖基金最近買賣了該股的股份。Tocqueville Asset Management L.P.在第一季度將其在 Immix Biopharma 的持股增加了 89.0%。Tocqueville Asset Management L.P.現在擁有該公司的 37,800 股股份，價值 116,000 美元，比上一季度增加了 17,800 股。Tritonpoint Wealth LLC 在第一季度收購了 Immix Biopharma 的新股份，價值 75,000 美元。Jump Financial LLC 在第四季度購買了 Immix Biopharma 的新股份，價值 128,000 美元。Private Advisor Group LLC 在第四季度收購了 Immix Biopharma 的新股份，價值 690,000 美元。最後，OLD National Bancorp IN 在第四季度購買了 Immix Biopharma 的新股份，價值 69,000 美元。機構投資者和對沖基金擁有公司股份的 11.26%。</p>
<h2>Immix Biopharma 公司簡介（獲取免費報告）</h2>
<p>Immix Biopharma, Inc 是一家臨牀階段的生物製藥公司，致力於在美國和澳大利亞開發腫瘤學和炎症領域的組織特異性治療藥物。該公司正在開發 IMX-110，該藥正在進行軟組織肉瘤和實體腫瘤的 1b/2a 期臨牀試驗；IMX-111，一種用於治療結直腸癌的組織特異性生物製劑；以及 IMX-120，一種用於治療潰瘍性結腸炎和嚴重克羅恩病的組織特異性生物製劑。</p>
<h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比 Immix Biopharma 更好</li>
<li>賣空：如何做空股票</li>
<li>這三家頂級銀行通過通過聯邦壓力測試後提高股息</li>
<li>為什麼特別股息對收入投資者來説是一個令人愉快的驚喜</li>
<li>搭乘 Lyft 股票在下半年實現兩位數增長</li>
<li>什麼是納斯達克證券交易所？</li>
<li>艾禮莉利股價上漲：GLP-1 Zepbound 瞄準睡眠呼吸暫停市場</li>
</ul>
<p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<p>→ 伊隆的下一個 IPO 可能比特斯拉還要大（來自 Paradigm Press）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx"/></p>
<h2>您現在是否應該投資 1000 美元購買 Immix Biopharma？</h2>
<p>在考慮投資 Immix Biopharma 之前，您可能希望聽聽這個。</p>
<p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票...而 Immix Biopharma 不在名單上。</p>
<p>儘管 Immix Biopharma 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

IMMX

<p>Immix Biopharma（納斯達克股票代碼：IMMX）在六月份經歷了空頭頭寸的顯著增加，較上個月增長了 39.7%。該公司的股票目前被空頭賣出比率為 3.1%，覆蓋天數比率為 3.6 天。股價為$2.12，12 個月最高價為$7.75，最低價為$1.55。Immix Biopharma 是一家專注於腫瘤學和炎症領域的組織特異性治療藥物開發的臨牀階段生物製藥公司</p>

<p>Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) was the target of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 473,100 shares, an increase of 39.7% from the May 31st total of 338,700 shares. Based on an average daily trading volume, of 131,400 shares, the short-interest ratio is currently 3.6 days. Currently, 3.1% of the company's shares are short sold.</p>
<div class="lb-trans"><p>Immix Biopharma, Inc.（納斯達克股票代碼：IMMX - 獲取免費報告）在六月份成為空頭頭寸顯著增加的目標。截至 6 月 15 日，空頭頭寸總計 473,100 股，比 5 月 31 日的 338,700 股增加了 39.7%。根據平均每日交易量 131,400 股，目前的空頭頭寸比率為 3.6 天。目前，公司股份中有 3.1% 被做空。</p>
</div><p>Get <strong>Immix Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Immix Biopharma</strong> 警報：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>Separately, HC Wainwright initiated coverage on Immix Biopharma in a report on Monday. They issued a &#34;buy&#34; rating and a $7.00 price objective on the stock.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在週一的一份報告中開始對 Immix Biopharma 進行覆蓋。他們對該股發出了 “買入” 評級，並設定了 7.00 美元的股價目標。</p>
</div><p><strong>View Our Latest Analysis on Immix Biopharma</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Immix Biopharma 的最新分析</strong></p>
</div><h2>Immix Biopharma Trading Up 7.1 %</h2>
<div class="lb-trans"><h2>Immix Biopharma 交易上漲 7.1%</h2>
</div><p>IMMX traded up $0.14 during trading hours on Monday, hitting $2.12. 109,687 shares of the company's stock were exchanged, compared to its average volume of 209,798. Immix Biopharma has a 12-month low of $1.55 and a 12-month high of $7.75. The firm has a market cap of $55.99 million, a P/E ratio of -2.28 and a beta of 0.17. The firm has a 50 day moving average of $2.16 and a 200 day moving average of $3.42.</p>
<div class="lb-trans"><p>IMMX 週一在交易時間內上漲了 0.14 美元，達到 2.12 美元。公司股票交易量為 109,687 股，相比其平均交易量 209,798 股有所下降。Immix Biopharma 的 12 個月最低價為 1.55 美元，最高價為 7.75 美元。該公司的市值為 5599 萬美元，市盈率為-2.28，貝塔係數為 0.17。公司的 50 天移動平均價為 2.16 美元，200 天移動平均價為 3.42 美元。</p>
</div><p>Immix Biopharma (NASDAQ:IMMX - Get Free Report) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, research analysts expect that Immix Biopharma will post -0.93 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Immix Biopharma（納斯達克股票代碼：IMMX - 獲取免費報告）上次公佈季度財報是在 5 月 9 日星期四。公司報告該季度每股收益為（0.22）美元，超過了（0.23）美元的共識預期。研究分析師羣體預計，Immix Biopharma 今年財政年度的每股收益將為-0.93 美元。</p>
</div><h2>Institutional Investors Weigh In On Immix Biopharma</h2>
<div class="lb-trans"><h2>機構投資者對 Immix Biopharma 的看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the stock. Tocqueville Asset Management L.P. raised its holdings in Immix Biopharma by 89.0% in the first quarter. Tocqueville Asset Management L.P. now owns 37,800 shares of the company's stock valued at $116,000 after acquiring an additional 17,800 shares in the last quarter. Tritonpoint Wealth LLC acquired a new stake in shares of Immix Biopharma in the 1st quarter valued at $75,000. Jump Financial LLC purchased a new stake in shares of Immix Biopharma during the 4th quarter worth $128,000. Private Advisor Group LLC acquired a new position in shares of Immix Biopharma during the fourth quarter worth $690,000. Finally, OLD National Bancorp IN purchased a new position in Immix Biopharma in the fourth quarter valued at $69,000. Institutional investors and hedge funds own 11.26% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近買賣了該股的股份。Tocqueville Asset Management L.P.在第一季度將其在 Immix Biopharma 的持股增加了 89.0%。Tocqueville Asset Management L.P.現在擁有該公司的 37,800 股股份，價值 116,000 美元，比上一季度增加了 17,800 股。Tritonpoint Wealth LLC 在第一季度收購了 Immix Biopharma 的新股份，價值 75,000 美元。Jump Financial LLC 在第四季度購買了 Immix Biopharma 的新股份，價值 128,000 美元。Private Advisor Group LLC 在第四季度收購了 Immix Biopharma 的新股份，價值 690,000 美元。最後，OLD National Bancorp IN 在第四季度購買了 Immix Biopharma 的新股份，價值 69,000 美元。機構投資者和對沖基金擁有公司股份的 11.26%。</p>
</div><h2>Immix Biopharma Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Immix Biopharma 公司簡介（獲取免費報告）</h2>
</div><p>Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.</p>
<div class="lb-trans"><p>Immix Biopharma, Inc 是一家臨牀階段的生物製藥公司，致力於在美國和澳大利亞開發腫瘤學和炎症領域的組織特異性治療藥物。該公司正在開發 IMX-110，該藥正在進行軟組織肉瘤和實體腫瘤的 1b/2a 期臨牀試驗；IMX-111，一種用於治療結直腸癌的組織特異性生物製劑；以及 IMX-120，一種用於治療潰瘍性結腸炎和嚴重克羅恩病的組織特異性生物製劑。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Immix Biopharma</li>
<li>Short Selling: How to Short a Stock</li>
<li>These Top 3 Banks Raise Dividends After Passing Fed Stress Test</li>
<li>Why Special Dividends Can be a Delightful Surprise for Income Investors</li>
<li>Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half</li>
<li>What is the NASDAQ Stock Exchange?</li>
<li>Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>我們喜歡的五隻股票比 Immix Biopharma 更好</li>
<li>賣空：如何做空股票</li>
<li>這三家頂級銀行通過通過聯邦壓力測試後提高股息</li>
<li>為什麼特別股息對收入投資者來説是一個令人愉快的驚喜</li>
<li>搭乘 Lyft 股票在下半年實現兩位數增長</li>
<li>什麼是納斯達克證券交易所？</li>
<li>艾禮莉利股價上漲：GLP-1 Zepbound 瞄準睡眠呼吸暫停市場</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由敍事科技和 MarketBeat 的財務數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><p>→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 伊隆的下一個 IPO 可能比特斯拉還要大（來自 Paradigm Press）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTgx" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8581&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Immix Biopharma right now?</h2>
<div class="lb-trans"><h2>您現在是否應該投資 1000 美元購買 Immix Biopharma？</h2>
</div><p>Before you consider Immix Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮投資 Immix Biopharma 之前，您可能希望聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟蹤華爾街頂級評級和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已確定了五隻頂級分析師悄悄告訴客户現在購買的股票...而 Immix Biopharma 不在名單上。</p>
</div><p>While Immix Biopharma currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Immix Biopharma 目前在分析師中有 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Immix Biopharma, Inc. (NASDAQ:IMMX) 空頭頭寸顯著增加